The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

Cited by papers we hold 6

• Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective · 2022
  No notice
• Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance · 2020
  No notice
• FGF/FGFR signaling in health and disease · 2020
  No notice
• Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors · 2019
  No notice
• Receptor Tyrosine Kinase-Targeted Cancer Therapy · 2018
  No notice
• Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.